首页 > 最新文献

Obstetrics and Gynecology Science最新文献

英文 中文
The effect of antioxidant supplementation on dysmenorrhea and endometriosis-associated painful symptoms: a systematic review and meta-analysis of randomized clinical trials. 抗氧化剂补充剂对痛经和子宫内膜异位症相关疼痛症状的影响:随机临床试验的系统回顾和荟萃分析。
IF 2 Q2 OBSTETRICS & GYNECOLOGY Pub Date : 2024-11-01 Epub Date: 2024-11-04 DOI: 10.5468/ogs.24228
Sedighe Esmaeilzadeh, Parvaneh Mirabi
{"title":"The effect of antioxidant supplementation on dysmenorrhea and endometriosis-associated painful symptoms: a systematic review and meta-analysis of randomized clinical trials.","authors":"Sedighe Esmaeilzadeh, Parvaneh Mirabi","doi":"10.5468/ogs.24228","DOIUrl":"10.5468/ogs.24228","url":null,"abstract":"","PeriodicalId":37602,"journal":{"name":"Obstetrics and Gynecology Science","volume":" ","pages":"586-587"},"PeriodicalIF":2.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142569695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lenvatinib and pembrolizumab versus platinum doublet chemotherapy as second-line therapy for advanced or recurrent endometrial cancer. 作为晚期或复发性子宫内膜癌的二线疗法,乐伐替尼和pembrolizumab与铂类双联化疗的比较。
IF 2 Q2 OBSTETRICS & GYNECOLOGY Pub Date : 2024-11-01 Epub Date: 2024-09-27 DOI: 10.5468/ogs.24075
Yutaka Yoneoka, Tsukuru Amano, Akimasa Takahashi, Hiroki Nishimura, Mari Deguchi, Hiroyuki Yamanaka, Yuji Tanaka, Shunichiro Tsuji, Takashi Murakami

Objective: There is no consensus on whether platinum doublet chemotherapy or lenvatinib and pembrolizumab (LEN/PEM) is superior for advanced or recurrent endometrial cancer. Thus, this study aimed to compare the prognosis and adverse events in patients with advanced or recurrent endometrial cancer treated with platinum doublet chemotherapy or LEN/PEM.

Methods: We retrospectively reviewed the medical records of patients who received platinum doublet chemotherapy or LEN/PEM at our institution for advanced or recurrent endometrial cancer and had a history of platinum-based chemotherapy between January 2013 and August 2023.

Results: During the study period, 11 regimens were identified in the platinum doublet chemotherapy group, and 11 regimens were identified in the LEN/PEM group. The objective response rates of the platinum doublet chemotherapy and LEN/ PEM groups were 36.4% and 54.5% (P=0.67), respectively. The 6-month progression-free survival (PFS) rates of the platinum doublet chemotherapy and LEN/PEM groups were 27.3% (95% confidence interval [CI], 13.8%-40.7%) and 70.0% (95% CI, 55.5%-84.5%), respectively. The differences were significant between the two groups. Multivariate analyses of histology, prior lines of chemotherapy, platinum-free intervals, and regimens revealed that the LEN/PEM group had significantly better PFS rates.

Conclusion: Treatment with LEN/PEM resulted in significantly longer PFS than that of treatment with platinum doublet chemotherapy in patients with advanced and recurrent endometrial cancer. However, further large-scale studies are required to validate these findings.

目的:对于铂类双药化疗或来那替尼和彭博利珠单抗(LEN/PEM)治疗晚期或复发性子宫内膜癌是否更优,目前尚未达成共识。因此,本研究旨在比较晚期或复发性子宫内膜癌患者接受铂类双药化疗或来那替尼/PEM治疗后的预后和不良事件:我们回顾性审查了2013年1月至2023年8月期间在我院接受铂类双药化疗或LEN/PEM治疗的晚期或复发性子宫内膜癌患者的病历,这些患者均有铂类化疗史:在研究期间,铂双药化疗组确定了11种方案,LEN/PEM组确定了11种方案。铂双t化疗组和LEN/PEM组的客观反应率分别为36.4%和54.5%(P=0.67)。铂双药化疗组和LEN/PEM组的6个月无进展生存期(PFS)分别为27.3%(95%置信区间[CI],13.8-40.7%)和70.0%(95% CI,55.5-84.5%)。两组之间差异显著。对组织学、之前的化疗方案、无铂间隔和治疗方案进行多变量分析后发现,LEN/PEM组的PFS率明显更高:结论:在晚期和复发性子宫内膜癌患者中,LEN/PEM治疗的PFS明显长于铂双联化疗。结论:在晚期和复发性子宫内膜癌患者中,LEN/PEM治疗的PFS明显长于铂类双药化疗。
{"title":"Lenvatinib and pembrolizumab versus platinum doublet chemotherapy as second-line therapy for advanced or recurrent endometrial cancer.","authors":"Yutaka Yoneoka, Tsukuru Amano, Akimasa Takahashi, Hiroki Nishimura, Mari Deguchi, Hiroyuki Yamanaka, Yuji Tanaka, Shunichiro Tsuji, Takashi Murakami","doi":"10.5468/ogs.24075","DOIUrl":"10.5468/ogs.24075","url":null,"abstract":"<p><strong>Objective: </strong>There is no consensus on whether platinum doublet chemotherapy or lenvatinib and pembrolizumab (LEN/PEM) is superior for advanced or recurrent endometrial cancer. Thus, this study aimed to compare the prognosis and adverse events in patients with advanced or recurrent endometrial cancer treated with platinum doublet chemotherapy or LEN/PEM.</p><p><strong>Methods: </strong>We retrospectively reviewed the medical records of patients who received platinum doublet chemotherapy or LEN/PEM at our institution for advanced or recurrent endometrial cancer and had a history of platinum-based chemotherapy between January 2013 and August 2023.</p><p><strong>Results: </strong>During the study period, 11 regimens were identified in the platinum doublet chemotherapy group, and 11 regimens were identified in the LEN/PEM group. The objective response rates of the platinum doublet chemotherapy and LEN/ PEM groups were 36.4% and 54.5% (P=0.67), respectively. The 6-month progression-free survival (PFS) rates of the platinum doublet chemotherapy and LEN/PEM groups were 27.3% (95% confidence interval [CI], 13.8%-40.7%) and 70.0% (95% CI, 55.5%-84.5%), respectively. The differences were significant between the two groups. Multivariate analyses of histology, prior lines of chemotherapy, platinum-free intervals, and regimens revealed that the LEN/PEM group had significantly better PFS rates.</p><p><strong>Conclusion: </strong>Treatment with LEN/PEM resulted in significantly longer PFS than that of treatment with platinum doublet chemotherapy in patients with advanced and recurrent endometrial cancer. However, further large-scale studies are required to validate these findings.</p>","PeriodicalId":37602,"journal":{"name":"Obstetrics and Gynecology Science","volume":" ","pages":"534-540"},"PeriodicalIF":2.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142355857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Incidence of excessive gestational weight gain among overweight and obese women. 超重和肥胖妇女妊娠体重增加过多的发生率。
IF 2 Q2 OBSTETRICS & GYNECOLOGY Pub Date : 2024-09-01 Epub Date: 2024-08-21 DOI: 10.5468/ogs.24122
Suphisara Maimaen, Kusol Russameecharoen, Dittakarn Boriboonhirunsarn

Objective: To determine the incidence of excessive gestational weight gain (GWG) among overweight and obese pregnant women, its associated factors, and pregnancy outcomes.

Methods: A total of 355 overweight or obese singleton pregnant women who were included. Obstetric characteristics, weight gain, and pregnancy outcomes, were extracted from medical records. GWG was categorized according to the Institute of Medicine recommendation. Comparisons were made between individuals with inadequate, normal, and excessive GWG. Logistic regression analysis was performed to determine independent associated factors for excessive GWG.

Results: Majority of the women were overweight (68.7%), 38.9% were nulliparous, and mean pre-pregnancy body mass index was 28.9 kg/m2. Excessive GWG was observed in 53% of the women. Women with excessive GWG had significantly higher weight gain in every trimester. Risk of excessive GWG increased in women ≤30 years, while gestational diabetes (GDM) significantly decreased the risk. Women with excessive GWG had a significantly higher primary cesarean section rate. Both women with normal and excessive GWG showed higher rate of having large for gestational age (LGA) infants (P=0.003). Maternal age of ≤30 years significantly increased the risk of excessive GWG (adjusted odds ratio [aOR], 1.91; 95% confidence interval [CI], 1.11-3.27) and GDM significantly decreased this risk (aOR, 0.40; 95% CI, 0.24-0.67).

Conclusion: The incidence of excessive GWG among overweight and obese women was 53%. Maternal age of ≤30 years significantly increased this risk while women with GDM were significantly decreased risk. Primary cesarean section and fetal LGA significantly increased in women with excessive GWG.

目的确定超重和肥胖孕妇妊娠体重增加过多(GWG)的发生率、相关因素和妊娠结局:方法:共纳入 355 名超重或肥胖的单胎孕妇,这些孕妇在 Siriraj 医院接受产前护理并分娩。产科特征、体重增加和妊娠结局等数据均来自医疗记录。GWG根据医学研究所的建议进行分类。对 GWG 不足、正常和过高的个体进行比较。进行了逻辑回归分析,以确定 GWG 过高的独立相关因素:结果:大多数妇女超重(68.7%),38.9%为无子宫,孕前平均体重指数为 28.9 kg/m2。53%的妇女体重超标。体重增长过快的妇女在每个孕期的体重增长都明显较高。妊娠体重超标的风险在年龄小于 30 岁的女性中有所增加,而妊娠糖尿病(GDM)则明显降低了这一风险。GWG过高的妇女的初次剖宫产率明显较高。GWG正常和GWG过高的妇女都有较高的胎龄儿巨大儿(LGA)率(P=0.003)。产妇年龄小于 30 岁会显著增加 GWG 超标的风险(调整后的几率比 [OR],1.91;95% 置信区间 [95%CI],1.11-3.27),而 GDM 会显著降低这一风险(调整后的几率比,0.40;95% CI,0.24-0.67):结论:超重和肥胖妇女的 GWG 过高发生率为 53%。结论:超重和肥胖妇女的 GWG 过高发生率为 53%,产妇年龄≤30 岁会显著增加这一风险,而患有 GDM 的妇女的风险则显著降低。初次剖宫产率和胎儿 LGA 率在 GWG 过高的妇女中明显增加。
{"title":"Incidence of excessive gestational weight gain among overweight and obese women.","authors":"Suphisara Maimaen, Kusol Russameecharoen, Dittakarn Boriboonhirunsarn","doi":"10.5468/ogs.24122","DOIUrl":"10.5468/ogs.24122","url":null,"abstract":"<p><strong>Objective: </strong>To determine the incidence of excessive gestational weight gain (GWG) among overweight and obese pregnant women, its associated factors, and pregnancy outcomes.</p><p><strong>Methods: </strong>A total of 355 overweight or obese singleton pregnant women who were included. Obstetric characteristics, weight gain, and pregnancy outcomes, were extracted from medical records. GWG was categorized according to the Institute of Medicine recommendation. Comparisons were made between individuals with inadequate, normal, and excessive GWG. Logistic regression analysis was performed to determine independent associated factors for excessive GWG.</p><p><strong>Results: </strong>Majority of the women were overweight (68.7%), 38.9% were nulliparous, and mean pre-pregnancy body mass index was 28.9 kg/m2. Excessive GWG was observed in 53% of the women. Women with excessive GWG had significantly higher weight gain in every trimester. Risk of excessive GWG increased in women ≤30 years, while gestational diabetes (GDM) significantly decreased the risk. Women with excessive GWG had a significantly higher primary cesarean section rate. Both women with normal and excessive GWG showed higher rate of having large for gestational age (LGA) infants (P=0.003). Maternal age of ≤30 years significantly increased the risk of excessive GWG (adjusted odds ratio [aOR], 1.91; 95% confidence interval [CI], 1.11-3.27) and GDM significantly decreased this risk (aOR, 0.40; 95% CI, 0.24-0.67).</p><p><strong>Conclusion: </strong>The incidence of excessive GWG among overweight and obese women was 53%. Maternal age of ≤30 years significantly increased this risk while women with GDM were significantly decreased risk. Primary cesarean section and fetal LGA significantly increased in women with excessive GWG.</p>","PeriodicalId":37602,"journal":{"name":"Obstetrics and Gynecology Science","volume":" ","pages":"489-496"},"PeriodicalIF":2.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11424190/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142019046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Genetic landscape of thrombophilia in recurrent miscarriages. 复发性流产中血栓性疾病的遗传情况。
IF 2 Q2 OBSTETRICS & GYNECOLOGY Pub Date : 2024-09-01 Epub Date: 2024-07-26 DOI: 10.5468/ogs.22084
Alina Athar, Poonam Kashyap, Shagufta Khan, Real Sumayya Abdul Sattar, Suhail Ahmed Khan, Sudha Prasad, Syed Akhtar Husain, Farah Parveen

The etiology of recurrent miscarriage (RM) is extremely heterogeneous, encompassing genetic, immunological, anatomical, endocrine, thrombophilic, infectious, and uterine abnormalities. Thrombophilia is a major contributor to pregnancy complications, potentially harming the fetus and jeopardizing the continuation of pregnancy. Therefore, successful pregnancy outcomes depend on maintaining a delicate balance between coagulation and fibrinolytic factors, crucial for ensuring the adjustment of the basal plate to facilitate adequate placental perfusion. Despite numerous studies shedding light on the role of thrombophilic factors and genetic variations in RM, the exact pathogenesis remains unclear. It is imperative to systematically rule out thrombophilia and other related factors responsible for pregnancy disorders and RMs to guide appropriate and active management strategies. Addressing thrombophilia continues to present challenges in terms of effective treatment. The current review aims to address the heterogeneity of RM as a therapeutic challenge, emphasizing the need for standardized diagnostic tests and welldesigned multicenter research trials to gather robust, evidence-based data on thrombophilic causes of RM and provide effective treatment. The goal is to enhance the understanding of thrombophilic factors and genetic landscapes associated with RM through various approaches, including candidate gene studies, genome-wide association studies, and high-throughput sequencing. Meta-analyses have underscored the significance of genetic aberrations in RM, highlighting the necessity for identifying critical mutations implicated in the etiopathogenesis of miscarriages to pave the way for implementation of targeted clinical therapies.

复发性流产(RM)的病因极为复杂,包括遗传、免疫、解剖、内分泌、血栓性、感染和子宫异常。血栓性疾病是导致妊娠并发症的主要因素,可能会伤害胎儿并危及妊娠的继续。因此,成功的妊娠结局取决于维持凝血因子和纤维蛋白溶解因子之间的微妙平衡,这对确保调整底板以促进胎盘充分灌注至关重要。尽管大量研究揭示了嗜血栓因子和遗传变异在 RM 中的作用,但确切的发病机制仍不清楚。当务之急是系统地排除血栓性疾病及其他导致妊娠障碍和RM的相关因素,以指导适当和积极的管理策略。针对血栓性疾病的有效治疗仍面临挑战。本综述旨在探讨 RM 作为治疗难题的异质性,强调需要标准化的诊断测试和精心设计的多中心研究试验,以收集有关血栓性 RM 病因的可靠循证数据,并提供有效的治疗。我们的目标是通过候选基因研究、全基因组关联研究和高通量测序等各种方法,加强对血栓嗜性因素和与 RM 相关的遗传景观的了解。Meta 分析强调了基因畸变在 RM 中的重要性,突出了确定与流产发病机制有关的关键突变的必要性,从而为实施有针对性的临床疗法铺平道路。
{"title":"Genetic landscape of thrombophilia in recurrent miscarriages.","authors":"Alina Athar, Poonam Kashyap, Shagufta Khan, Real Sumayya Abdul Sattar, Suhail Ahmed Khan, Sudha Prasad, Syed Akhtar Husain, Farah Parveen","doi":"10.5468/ogs.22084","DOIUrl":"10.5468/ogs.22084","url":null,"abstract":"<p><p>The etiology of recurrent miscarriage (RM) is extremely heterogeneous, encompassing genetic, immunological, anatomical, endocrine, thrombophilic, infectious, and uterine abnormalities. Thrombophilia is a major contributor to pregnancy complications, potentially harming the fetus and jeopardizing the continuation of pregnancy. Therefore, successful pregnancy outcomes depend on maintaining a delicate balance between coagulation and fibrinolytic factors, crucial for ensuring the adjustment of the basal plate to facilitate adequate placental perfusion. Despite numerous studies shedding light on the role of thrombophilic factors and genetic variations in RM, the exact pathogenesis remains unclear. It is imperative to systematically rule out thrombophilia and other related factors responsible for pregnancy disorders and RMs to guide appropriate and active management strategies. Addressing thrombophilia continues to present challenges in terms of effective treatment. The current review aims to address the heterogeneity of RM as a therapeutic challenge, emphasizing the need for standardized diagnostic tests and welldesigned multicenter research trials to gather robust, evidence-based data on thrombophilic causes of RM and provide effective treatment. The goal is to enhance the understanding of thrombophilic factors and genetic landscapes associated with RM through various approaches, including candidate gene studies, genome-wide association studies, and high-throughput sequencing. Meta-analyses have underscored the significance of genetic aberrations in RM, highlighting the necessity for identifying critical mutations implicated in the etiopathogenesis of miscarriages to pave the way for implementation of targeted clinical therapies.</p>","PeriodicalId":37602,"journal":{"name":"Obstetrics and Gynecology Science","volume":" ","pages":"435-448"},"PeriodicalIF":2.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11424186/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141789301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Phospholipase C zeta: a hidden face of sperm for oocyte activation and early embryonic development. 磷脂酶 C zeta:精子激活卵母细胞和早期胚胎发育的隐藏面孔。
IF 2 Q2 OBSTETRICS & GYNECOLOGY Pub Date : 2024-09-01 Epub Date: 2024-08-01 DOI: 10.5468/ogs.24019
Soukaina Azil, Modou Mamoune Mbaye, Noureddine Louanjli, Bouchra Ghazi, Moncef Benkhalifa

Oocyte activation is a fundamental event in mammalian fertilization and is initiated by a cascade of calcium signaling and oscillation pathways. Phospholipase C zeta (PLCζ) is involved in modulating cortical granule exocytosis, releasing oocyte meiotic arrest, regulating gene expression, and early embryogenesis. These processes are considered to be initiated and controlled by PLCζ activity via the inositol-1,4,5-triphosphate pathway. The decrease or absence of functional PLCζ due to mutational defects in protein expression or maintenance can impair male fertility. In this literature review, we highlight the significance of PLCζ as a sperm factor involved in oocyte activation, its mechanism of action, the signaling pathway involved, and its close association with oocyte activation. Finally, we discuss the relationship between male infertility and PLCζ deficiency.

卵母细胞活化是哺乳动物受精过程中的基本事件,由一连串的钙信号和振荡途径启动。磷脂酶 C zeta(PLCζ)参与调节皮质颗粒外泌、释放卵母细胞减数分裂停滞、调节基因表达和早期胚胎发生。这些过程被认为是由 PLCζ 的活性通过肌醇-1,4,5-三磷酸途径启动和控制的。由于蛋白质表达或维持的突变缺陷,功能性 PLCζ 的减少或缺失会损害男性生育能力。在这篇文献综述中,我们强调了 PLCζ 作为精子因子参与卵母细胞活化的重要意义、其作用机制、所涉及的信号通路及其与卵母细胞活化的密切关系。最后,我们讨论了男性不育与 PLCζ 缺乏之间的关系。
{"title":"Phospholipase C zeta: a hidden face of sperm for oocyte activation and early embryonic development.","authors":"Soukaina Azil, Modou Mamoune Mbaye, Noureddine Louanjli, Bouchra Ghazi, Moncef Benkhalifa","doi":"10.5468/ogs.24019","DOIUrl":"10.5468/ogs.24019","url":null,"abstract":"<p><p>Oocyte activation is a fundamental event in mammalian fertilization and is initiated by a cascade of calcium signaling and oscillation pathways. Phospholipase C zeta (PLCζ) is involved in modulating cortical granule exocytosis, releasing oocyte meiotic arrest, regulating gene expression, and early embryogenesis. These processes are considered to be initiated and controlled by PLCζ activity via the inositol-1,4,5-triphosphate pathway. The decrease or absence of functional PLCζ due to mutational defects in protein expression or maintenance can impair male fertility. In this literature review, we highlight the significance of PLCζ as a sperm factor involved in oocyte activation, its mechanism of action, the signaling pathway involved, and its close association with oocyte activation. Finally, we discuss the relationship between male infertility and PLCζ deficiency.</p>","PeriodicalId":37602,"journal":{"name":"Obstetrics and Gynecology Science","volume":" ","pages":"467-480"},"PeriodicalIF":2.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11424188/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141861165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The evolving landscape of immunohistochemistry in cervical and uterine carcinoma in gynecologic oncology: current status and future directions. 妇科肿瘤学中宫颈癌和子宫癌免疫组化的演变:现状和未来方向。
IF 2 Q2 OBSTETRICS & GYNECOLOGY Pub Date : 2024-09-01 Epub Date: 2024-09-04 DOI: 10.5468/ogs.24120
Sumedha Gupta, Sana Ahuja, Dheer Singh Kalwaniya

Immunohistochemistry (IHC) has become an indispensable tool in routine gynecological pathology, particularly with the advancements in molecular understanding and histological classification of gynecological cancers. This evolution has led to new immunostainings for diagnostic and classification purposes. This review describes the diagnostic utility of IHC in gynecological neoplasms, drawing insights from literature reviews, personal experiences, and research findings. It delves into the application of IHC in resolving morphologically equivocal cases, emphasizing its role in achieving an accurate diagnosis. The selection of appropriate immunomarkers for common scenarios encountered in gynecological pathology aids pathologists in navigating complex cases. Specifically, we focus on cervical and endometrial malignancies, elucidating the molecular rationale behind the use of specific immunohistochemical markers. An updated overview of essential immunohistochemical markers provides knowledge for precise diagnosis and classification of gynecological cancers. This review serves as a valuable resource for clinicians and researchers involved in the management and study of gynecological malignancies, facilitating improved patient care and outcomes.

免疫组化(IHC)已成为常规妇科病理学中不可或缺的工具,尤其是随着对妇科癌症的分子认识和组织学分类的进步。这种演变催生了用于诊断和分类的新型免疫染色。本综述从文献综述、个人经验和研究结果中汲取灵感,阐述了 IHC 在妇科肿瘤中的诊断作用。它深入探讨了 IHC 在解决形态不明确病例中的应用,强调了 IHC 在实现准确诊断中的作用。针对妇科病理学中常见的情况选择适当的免疫标记物有助于病理学家处理复杂的病例。我们特别关注宫颈和子宫内膜恶性肿瘤,阐明了使用特定免疫组化标记物的分子原理。对基本免疫组化标记物的最新概述为妇科癌症的精确诊断和分类提供了知识。这本综述是从事妇科恶性肿瘤管理和研究的临床医生和研究人员的宝贵资源,有助于改善患者护理和治疗效果。
{"title":"The evolving landscape of immunohistochemistry in cervical and uterine carcinoma in gynecologic oncology: current status and future directions.","authors":"Sumedha Gupta, Sana Ahuja, Dheer Singh Kalwaniya","doi":"10.5468/ogs.24120","DOIUrl":"10.5468/ogs.24120","url":null,"abstract":"<p><p>Immunohistochemistry (IHC) has become an indispensable tool in routine gynecological pathology, particularly with the advancements in molecular understanding and histological classification of gynecological cancers. This evolution has led to new immunostainings for diagnostic and classification purposes. This review describes the diagnostic utility of IHC in gynecological neoplasms, drawing insights from literature reviews, personal experiences, and research findings. It delves into the application of IHC in resolving morphologically equivocal cases, emphasizing its role in achieving an accurate diagnosis. The selection of appropriate immunomarkers for common scenarios encountered in gynecological pathology aids pathologists in navigating complex cases. Specifically, we focus on cervical and endometrial malignancies, elucidating the molecular rationale behind the use of specific immunohistochemical markers. An updated overview of essential immunohistochemical markers provides knowledge for precise diagnosis and classification of gynecological cancers. This review serves as a valuable resource for clinicians and researchers involved in the management and study of gynecological malignancies, facilitating improved patient care and outcomes.</p>","PeriodicalId":37602,"journal":{"name":"Obstetrics and Gynecology Science","volume":" ","pages":"449-466"},"PeriodicalIF":2.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11424185/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142134116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence and risk factors of urinary incontinence in pregnant Korean women. 韩国孕妇尿失禁的患病率和风险因素。
IF 2 Q2 OBSTETRICS & GYNECOLOGY Pub Date : 2024-09-01 Epub Date: 2024-08-21 DOI: 10.5468/ogs.24156
Hwisu Jung, Dong Won Hwang, Kyoung-Chul Chun, Young Ah Kim, Jae Whoan Koh, Jung Yeol Han, Hae Do Jung, Dal Soo Hong, Jeong Sup Yun

Objective: This study aimed to evaluate the prevalence of urinary incontinence (UI) and its associated risk factors among pregnant Korean women, as UI significantly impacts their quality of life.

Methods: A cross-sectional study involving singleton pregnant women was conducted between April and December 2023. Data were collected using a questionnaire assessing demographic information and UI symptoms. The International Consultation on Incontinence Questionnaire-UI short form was used to diagnose UI.

Results: A total of 824 pregnant women from three centers participated, with an overall prenatal UI prevalence of 40.2% (331/824). Stress UI was most common (77.1%), followed by mixed UI (16.9%), and urgency UI (6.0%). Risk factors for UI included prior delivery mode, specifically vaginal delivery (adjusted odds ratio [aOR], 5.61; 95% confidence interval [CI], 1.40-22.50; P=0.015) and combined vaginal and cesarean delivery (aOR, 23.14; 95% CI, 1.77-302.74; P=0.017). Additionally, second trimester (aOR, 1.99; 95% CI, 1.19-3.32; P=0.009) and third trimester (aOR, 4.44; 95% CI, 2.65-7.40; P<0.001) were associated with increased UI risk. Conversely, drinking alcohol before pregnancy was a protective factor (aOR, 0.72; 95% CI, 0.53-0.99; P=0.046).

Conclusion: Approximately 40% of Korean pregnant women experience prenatal UI. Prior delivery mode and advanced gastrointestinal age are significant risk factors. Further research with postpartum and long-term follow-ups is needed.

摘要本研究旨在评估韩国孕妇尿失禁(UI)的患病率及其相关风险因素,因为尿失禁严重影响她们的生活质量:方法:2023 年 4 月至 12 月期间,对单胎孕妇进行了一项横断面研究。研究采用问卷调查的方式收集数据,评估人口统计学信息和尿失禁症状。国际尿失禁咨询问卷-UI简表用于诊断尿失禁:共有来自三个中心的 824 名孕妇参与,产前尿失禁总患病率为 40.2%(331/824)。压力性尿失禁最常见(77.0%),其次是混合性尿失禁(16.9%)和急迫性尿失禁(6.0%)。UI 的风险因素包括之前的分娩方式,特别是阴道分娩(调整后的几率比 [aOR],5.6;95% 置信区间 [CI],1.40-22.50;P=0.015)以及阴道分娩和剖宫产联合分娩(aOR,23.14;95% CI,1.77-302.74;P=0.017)。此外,第二胎(aOR,1.99;95% CI,1.19-3.32;P=0.009)和第三胎(aOR,4.43;95% CI,2.65-7.40;PC 结论:约有 40% 的韩国孕妇经历过产前尿失禁。之前的分娩方式和胃肠道高龄是重要的风险因素。需要对产后和长期随访进行进一步研究。
{"title":"Prevalence and risk factors of urinary incontinence in pregnant Korean women.","authors":"Hwisu Jung, Dong Won Hwang, Kyoung-Chul Chun, Young Ah Kim, Jae Whoan Koh, Jung Yeol Han, Hae Do Jung, Dal Soo Hong, Jeong Sup Yun","doi":"10.5468/ogs.24156","DOIUrl":"10.5468/ogs.24156","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to evaluate the prevalence of urinary incontinence (UI) and its associated risk factors among pregnant Korean women, as UI significantly impacts their quality of life.</p><p><strong>Methods: </strong>A cross-sectional study involving singleton pregnant women was conducted between April and December 2023. Data were collected using a questionnaire assessing demographic information and UI symptoms. The International Consultation on Incontinence Questionnaire-UI short form was used to diagnose UI.</p><p><strong>Results: </strong>A total of 824 pregnant women from three centers participated, with an overall prenatal UI prevalence of 40.2% (331/824). Stress UI was most common (77.1%), followed by mixed UI (16.9%), and urgency UI (6.0%). Risk factors for UI included prior delivery mode, specifically vaginal delivery (adjusted odds ratio [aOR], 5.61; 95% confidence interval [CI], 1.40-22.50; P=0.015) and combined vaginal and cesarean delivery (aOR, 23.14; 95% CI, 1.77-302.74; P=0.017). Additionally, second trimester (aOR, 1.99; 95% CI, 1.19-3.32; P=0.009) and third trimester (aOR, 4.44; 95% CI, 2.65-7.40; P<0.001) were associated with increased UI risk. Conversely, drinking alcohol before pregnancy was a protective factor (aOR, 0.72; 95% CI, 0.53-0.99; P=0.046).</p><p><strong>Conclusion: </strong>Approximately 40% of Korean pregnant women experience prenatal UI. Prior delivery mode and advanced gastrointestinal age are significant risk factors. Further research with postpartum and long-term follow-ups is needed.</p>","PeriodicalId":37602,"journal":{"name":"Obstetrics and Gynecology Science","volume":" ","pages":"481-488"},"PeriodicalIF":2.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11424187/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142019047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Detection of trisomy 9 mosaicism in the second trimester screening by abnormal level of biochemical markers. 通过生化标记物的异常水平在第二孕期筛查中发现 9 三体嵌合。
IF 2 Q2 OBSTETRICS & GYNECOLOGY Pub Date : 2024-09-01 Epub Date: 2024-08-27 DOI: 10.5468/ogs.24062
Zohre Salari, Arman Moradi, Mahdiyeh Moudi, Zohre Mousavi

Trisomy 9 is a rare chromosomal abnormality that occurs in both mosaic and non-mosaic states. The present study reports a case of mosaic trisomy 9 detected during pregnancy in a 41-year-old woman in the second trimester screening. Maternal serum screening results were used to diagnose a chromosomal abnormality in utero. The results were validated by karyotyping. High levels of alpha-fetoprotein and low levels of unconjugated estriol (uE3), human chorionic gonadotropin (hCG), and inhibin A indicate a high risk for chromosomal abnormalities, including trisomy 18. Amniotic fluid karyotyping revealed 47, XX, +9 (30)/46, XX (20) in the fetus. Because a high level (60%) of mosaicism for trisomy 9 in the fetus can affect many parts of the body, the pregnancy was terminated. It seems that a significant reduction in the levels of hCG and uE3 is an informative marker for the detection of chromosomal abnormalities such as trisomy 9.

9 三体综合征是一种罕见的染色体异常,有镶嵌和非镶嵌两种状态。本研究报告了一例镶嵌型 9 三体综合征病例,患者为一名 41 岁女性,在妊娠中期筛查中发现。母体血清筛查结果用于诊断宫内染色体异常。结果通过核型分析得到验证。高水平的甲胎蛋白和低水平的非结合雌三醇(uE3)、人绒毛膜促性腺激素(hCG)和抑制素 A 表明染色体异常的风险很高,包括 18 三体综合征。羊水核型检查显示胎儿为 47,XX,+9(30)/46,XX(20)。由于胎儿中 9 三体综合征的嵌合程度很高(60%),可能会影响身体的多个部位,因此孕妇被终止妊娠。hCG 和 uE3 水平的显著降低似乎是检测染色体异常(如 9 三体)的一个信息标记。
{"title":"Detection of trisomy 9 mosaicism in the second trimester screening by abnormal level of biochemical markers.","authors":"Zohre Salari, Arman Moradi, Mahdiyeh Moudi, Zohre Mousavi","doi":"10.5468/ogs.24062","DOIUrl":"10.5468/ogs.24062","url":null,"abstract":"<p><p>Trisomy 9 is a rare chromosomal abnormality that occurs in both mosaic and non-mosaic states. The present study reports a case of mosaic trisomy 9 detected during pregnancy in a 41-year-old woman in the second trimester screening. Maternal serum screening results were used to diagnose a chromosomal abnormality in utero. The results were validated by karyotyping. High levels of alpha-fetoprotein and low levels of unconjugated estriol (uE3), human chorionic gonadotropin (hCG), and inhibin A indicate a high risk for chromosomal abnormalities, including trisomy 18. Amniotic fluid karyotyping revealed 47, XX, +9 (30)/46, XX (20) in the fetus. Because a high level (60%) of mosaicism for trisomy 9 in the fetus can affect many parts of the body, the pregnancy was terminated. It seems that a significant reduction in the levels of hCG and uE3 is an informative marker for the detection of chromosomal abnormalities such as trisomy 9.</p>","PeriodicalId":37602,"journal":{"name":"Obstetrics and Gynecology Science","volume":" ","pages":"506-510"},"PeriodicalIF":2.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11424189/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142082088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Does it affect the live birth rates to have a maximum endometrial thickness of 7, 8, or 9 mm in in-vitro fertilization-embryo transfer cycles? 在体外受精-胚胎移植周期中,子宫内膜最大厚度为 7、8 或 9 毫米是否会影响活产率?
IF 2 Q2 OBSTETRICS & GYNECOLOGY Pub Date : 2024-09-01 Epub Date: 2024-08-02 DOI: 10.5468/ogs.22316
Einav Kadour-Peero, Ido Feferkorn, Shirel Hadad-Liven, Michael H Dahan

Objective: To assess the effect of endometrial thickness (EMT) on live birth rates (LBR) in women with endometrial lining between 7.0-9.9 mm.

Methods: This retrospective cohort study included women who underwent fresh and frozen embryo transfers between 2008 and 2018, grouped according to their maximum EMT; group 1, 7.0-7.9 mm; group 2, 8.0-8.9 mm; and group 3, 9.0-9.9 mm and underwent blastocyst transfer.

Results: The study included 7,091 in-vitro fertilization cycles: 1,385 in group 1, 3,000 in group 2, and 2,706 in group 3. The combined LBR was 22.2%. The mean age of women at oocyte retrieval day was 36.7±4.5 years. There was no difference in female age at oocyte retrieval or in the quality of embryos transferred between the three groups. Group 1 had more diagnoses of diminished ovarian reserve (25.8% vs. 19.5% and 19.1%; p<0.001) and less male factor infertility compared with group 2 and 3, respectively (25.0% vs. 28.8% and 28.5%; P=0.024). LBR was higher with increasing endometrial thickness, group 2 vs. group 1 (22.0% vs. 17.4%; P=0.0004), group 3 vs. group 1 (25.0% vs. 17.2%; p<0.001), and group 3 vs. group 2 (25.0% vs. 22.0%; P=0.008). After controlling for confounding factors, these three groups did not differ in LBR (group 1 vs. group 2, odds ratio [OR], 1.08; 95% confidence interval [CI], 0.83-1.4; P=0.54 and group 1 vs. group 3, OR, 1.16; 95% CI, 0.90-1.51; P=0.24).

Conclusion: Live birth rates in women with endometrial thickness between 7.0-9.9 mm were not affected by different cut-offs when blastocyst transfer was performed.

目的评估子宫内膜厚度(EMT)对子宫内膜厚度在7.0-9.9毫米之间的妇女的活产率(LBR)的影响:这项回顾性队列研究纳入了 2008 年至 2018 年间接受新鲜胚胎移植和冷冻胚胎移植的女性,根据其最大 EMT 进行分组:第 1 组:7.0-7.9 mm,第 2 组:8.0-8.9 mm,第 3 组:9.0-9.9 mm,并接受囊胚移植:研究包括 7091 个体外受精周期:综合 LBR 为 22.2%。取卵日女性的平均年龄为(36.2±4.5)岁。三组妇女取卵时的年龄和移植胚胎的质量没有差异。与第 2 组和第 3 组相比,第 1 组诊断出卵巢储备功能减退的比例更高(25.5% 对 19.5% 和 19.1%;P=0.001),而男性因素不孕症的比例较低(25.0% 对 28.8% 和 28.5%;P=0.02)。随着子宫内膜厚度的增加,活产率越高,第 2 组与第 1 组相比(22.0% 对 17.4%;P=0.0004),第 3 组与第 1 组相比(25.0% 对 17.2%;P=0.001):在进行囊胚移植时,子宫内膜厚度在 7.0-9.9 mm 之间的妇女的活产率不受不同截止值的影响。
{"title":"Does it affect the live birth rates to have a maximum endometrial thickness of 7, 8, or 9 mm in in-vitro fertilization-embryo transfer cycles?","authors":"Einav Kadour-Peero, Ido Feferkorn, Shirel Hadad-Liven, Michael H Dahan","doi":"10.5468/ogs.22316","DOIUrl":"10.5468/ogs.22316","url":null,"abstract":"<p><strong>Objective: </strong>To assess the effect of endometrial thickness (EMT) on live birth rates (LBR) in women with endometrial lining between 7.0-9.9 mm.</p><p><strong>Methods: </strong>This retrospective cohort study included women who underwent fresh and frozen embryo transfers between 2008 and 2018, grouped according to their maximum EMT; group 1, 7.0-7.9 mm; group 2, 8.0-8.9 mm; and group 3, 9.0-9.9 mm and underwent blastocyst transfer.</p><p><strong>Results: </strong>The study included 7,091 in-vitro fertilization cycles: 1,385 in group 1, 3,000 in group 2, and 2,706 in group 3. The combined LBR was 22.2%. The mean age of women at oocyte retrieval day was 36.7±4.5 years. There was no difference in female age at oocyte retrieval or in the quality of embryos transferred between the three groups. Group 1 had more diagnoses of diminished ovarian reserve (25.8% vs. 19.5% and 19.1%; p<0.001) and less male factor infertility compared with group 2 and 3, respectively (25.0% vs. 28.8% and 28.5%; P=0.024). LBR was higher with increasing endometrial thickness, group 2 vs. group 1 (22.0% vs. 17.4%; P=0.0004), group 3 vs. group 1 (25.0% vs. 17.2%; p<0.001), and group 3 vs. group 2 (25.0% vs. 22.0%; P=0.008). After controlling for confounding factors, these three groups did not differ in LBR (group 1 vs. group 2, odds ratio [OR], 1.08; 95% confidence interval [CI], 0.83-1.4; P=0.54 and group 1 vs. group 3, OR, 1.16; 95% CI, 0.90-1.51; P=0.24).</p><p><strong>Conclusion: </strong>Live birth rates in women with endometrial thickness between 7.0-9.9 mm were not affected by different cut-offs when blastocyst transfer was performed.</p>","PeriodicalId":37602,"journal":{"name":"Obstetrics and Gynecology Science","volume":" ","pages":"497-505"},"PeriodicalIF":2.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11424184/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141876200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
WITHDRAWN: Embarking on life's blueprint: investigating the crucial involvement of extracellular vesicles in embryo development. 踏上生命的蓝图:研究细胞外囊泡在胚胎发育中的关键作用。
IF 2 Q2 OBSTETRICS & GYNECOLOGY Pub Date : 2024-08-09 DOI: 10.5468/ogs.24084
Seok Hee Lee

Ahead of print article withdrawn at the author's request due to administrative errors in the journal's processing of the submission.

细胞外囊泡(EVs)含有生物分子,如蛋白质、脂类和多种核酸,可改变受体细胞的各种生理和病理过程。本综述从EVs的生物学特性、对胚胎发育的影响以及治疗生殖系统疾病的潜在治疗价值等方面探讨了目前对EVs的认识。从受精到着床前阶段,以及在胚胎发育、细胞分化和器官形成过程中,EVs 在早期胚胎发育中发挥着至关重要的作用。在胚胎着床前,EVs 与母体生殖组织相互作用,促进着床接受能力;在胚胎着床过程中,EVs 调节细胞分化,促进组织形成和维持。EVs 中的异常生物活性分子与发育障碍有关,因此 EVs 可作为生物标记物。此外,EVs 还是潜在的治疗剂,可将遗传物质输送到目标组织或器官。本综述的研究结果强调了 EVs 在胚胎发育过程中细胞间信号传递的潜在作用。这将有助于推进辅助生殖技术和疗法,克服不孕症和发育障碍。
{"title":"WITHDRAWN: Embarking on life's blueprint: investigating the crucial involvement of extracellular vesicles in embryo development.","authors":"Seok Hee Lee","doi":"10.5468/ogs.24084","DOIUrl":"10.5468/ogs.24084","url":null,"abstract":"<p><p>Ahead of print article withdrawn at the author's request due to administrative errors in the journal's processing of the submission.</p>","PeriodicalId":37602,"journal":{"name":"Obstetrics and Gynecology Science","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2024-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141907903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Obstetrics and Gynecology Science
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1